Evidence map›Paper›PMID 41294899›Full record

ReviewDiseases (Basel, Switzerland)2025

Type 3 Diabetes: Linking Insulin Resistance to Cognitive Decline.

Brooke Chapple, Emily Bayliss, Seth Woodfin, Merritt Smith, Jeremiah Winter, William Moore

Abstract readReview
In one paragraph

Review in Diseases (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Neuroprotective effects ofFrontiers in nutrition · 2026
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Brooke ChappleDepartment of Biology and Chemistry, School of Health Sciences, Liberty University, Lynchburg, VA 24515, USA.
Emily BaylissDepartment of Biology and Chemistry, School of Health Sciences, Liberty University, Lynchburg, VA 24515, USA.ORCID 0009-0002-1071-3218
Seth WoodfinDepartment of Biomedical Sciences, West Virginia School of Osteopathic Medicine, Lewisburg, WV 24901, USA.
Merritt SmithDepartment of Biology and Chemistry, School of Health Sciences, Liberty University, Lynchburg, VA 24515, USA.
Jeremiah WinterDepartment of Biology and Chemistry, School of Health Sciences, Liberty University, Lynchburg, VA 24515, USA.
William MooreDepartment of Biology and Chemistry, School of Health Sciences, Liberty University, Lynchburg, VA 24515, USA.ORCID 0000-0002-2979-3660

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 3 diabetes (T3D) is characterized by chronic insulin resistance and insulin deficiency in the brain, leading to neuronal death, inflammation, oxidative stress, apoptosis, and synaptic dysfunction. These pathological processes contribute to cognitive decline and neurodegenerative disorders such as Alzheimer's disease. However, despite increasing evidence that links insulin resistance to cognitive impairment, the precise mechanisms that underly T3D remain largely unknown. This highlights a critical gap in research and potential therapeutic strategies. Given the significant impact of diet on metabolic health, investigating the correlation between the gut-brain axis may offer novel insights into the prevention and management of T3D. This review aims to elucidate the potential connections between insulin resistance and cognitive decline while also proposing interventions to slow aging and reduce the risk of early cognitive decline. At the same time, we acknowledge that the classification of type 3 diabetes is debatable and there is uncertainty as to whether insulin resistance is a primary driver or secondary manifestation of neurodegeneration.

Indexed as

Alzheimer’s diseasecognitive declinegut–brain axisinsulin resistancemetabolic healthneurodegenerationneuroinflammationoxidative stresssynaptic dysfunctiontype 3 diabetes

Identifiers

PMID41294899
PMCPMC12651046

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.